Reply to Letter to the Editor: Efficacy and Safety of Romosozumab Among Postmenopausal Women With Osteoporosis and Mild-to-Moderate Chronic Kidney Disease
- PMID: 36698050
- DOI: 10.1002/jbmr.4761
Reply to Letter to the Editor: Efficacy and Safety of Romosozumab Among Postmenopausal Women With Osteoporosis and Mild-to-Moderate Chronic Kidney Disease
Comment on
-
Efficacy and Safety of Romosozumab Among Postmenopausal Women With Osteoporosis and Mild-to-Moderate Chronic Kidney Disease.J Bone Miner Res. 2022 Aug;37(8):1437-1445. doi: 10.1002/jbmr.4563. Epub 2022 May 20. J Bone Miner Res. 2022. PMID: 35466448 Free PMC article. Clinical Trial.
-
Romosozumab Use and Cardiovascular Events.J Bone Miner Res. 2023 Mar;38(3):452-453. doi: 10.1002/jbmr.4695. Epub 2022 Sep 20. J Bone Miner Res. 2023. PMID: 36127855 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical

